Pfizer Clarifies XBRL Filing for September 2025 Results

Pfizer Limited responds to NSE query regarding XBRL submission of unaudited financial results for Q2/H1 FY2026.
Company clarifies initial filing error where 'Reporting Quarter' was incorrectly selected as 'Half Year' instead of 'Second quarter'.
Pfizer submitted a revised Integrated Filing - Financials XBRL on November 28, 2025, to correct the reporting type.
The document includes NSE acknowledgement of the revised XBRL submission for the period ended September 30, 2025.